MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Shareholders with Major Losses Invited to Lead Securities Class Action

On November 18, 2025, the law firm Robbins Geller Rudman & Dowd LLP (“RGRD”) announced a securities class‑action lawsuit titled Peters v. MoonLake Immunotherapeutics, No. 25‑cv‑08612 (S.D.N.Y.), targeting MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) and certain of its executives. The complaint alleges violations of the Securities Exchange Act of 1934 by MoonLake and its leadership, and invites investors who purchased or acquired MoonLake common stock during the class period and suffered substantial losses to step forward and seek appointment as lead plaintiff. MoonLake is a clinical‑stage biotech company focused on therapies for inflammatory skin and joint diseases, with its only drug candidate, sonelokimab (“SLK”), being developed for treatment of hidradenitis suppurativa (HS). The complaint asserts that the defendants made false or misleading statements and/or omitted material facts, specifically: That SLK and BIMZELX (an FDA‑approved monoclonal antibody for HS) share the same molecular targets — IL‑17A and IL‑17F. That SLK’s nanobody architecture would not necessarily confer a superior clinical benefit over BIMZELX’s traditional monoclonal structure. That the increased tissue penetration attributed to the nanobody structure would not translate into improved clinical efficacy. According to the complaint, on September 28 2025 MoonLake announced 16‑week Phase 3 VELA programme results showing SLK failed to demonstrate competitive efficacy relative to BIMZELX. The company’s stock price fell by nearly 90% following this announcement. Under the Private Securities Litigation Reform Act of 1995, any investor who purchased or acquired MoonLake common stock during the class period may move to be appointed lead plaintiff. The lead plaintiff is typically the investor with the largest financial interest and who otherwise meets the criteria of being typical and adequate of the class. That investor will have authority to select the law firm and steer the litigation. The deadline to file a motion for lead plaintiff in the Peters v. MoonLake action is Monday, December 15, 2025. Investors can contact RGRD via the firm’s online form or by phone at 800‑449‑4900, email . About RGRD: The firm claims to be one of the world’s leading plaintiffs’ firms specializing in securities fraud and shareholder litigation. It reportedly secured more than US $2.5 billion in investor recoveries in 2024 and has been ranked number one by ISS Securities Class Action Services four out of the last five years. #MoonLakeImmunotherapeutics #SecuritiesClassAction #InvestorAlert #BiotechLitigation #SlimScan #GrowthStocks #CANSLIM